News

Primary Screening Case Study

At Pelago Bioscience, we offer a high-throughput screening service based on CETSA® – a transformative, label-free assay for target engagement quantification in physiologically relevant contexts. This case study illustrates how employing high-throughput screening with CETSA can deliver…

Read more

ELRIG Research & Innovation 2024

We are thrilled to share that we will be showcasing our high-throughput services at ELRIG Research & Innovation 2024 in Manchester! Join us at The University of Manchester to explore how our offerings can support your Drug Discovery journey. We…

Read more

SLAS 2024

We are thrilled to share that we will be showcasing our high-throughput services at SLAS2024 in Boston! Join us at the Boston Convention and Exhibition Center to explore how our offerings can support your Drug Discovery journey. We look forward…

Read more

Discovery US 2023

The starting point for any desired biological effect is a drug-target interaction, an interaction that can be studied in a live cellular setting using the CETSA® technology. Drug hunters are now expanding the therapeutic target space to include harder to…

Read more

ELRIG – DRUG DISCOVERY 2023

Learn how Pelago Bioscience and our technology CETSA®, Cellular Thermal Shift Assay can help you assess target engagement, and bring your projects forward with confidence through: • Physiologically relevant, robust data • Completely label-free • Transferability across matrices…

Read more

6th Targeted Protein Degradation Summit

Protein degradation is a novel modality with the potential to tackle therapeutically interesting proteins previously seen as undruggable. In this area, CETSA® is a powerful technology for identifying binders, investigating target engagement and the mechanism of action of the protein…

Read more

BioJapan 23

CETSA® by Pelago Bioscience is a well-proven, best-in-class technology used to assess cellular protein-compound binding in cell. CETSA® can be applied throughout all steps of the drug discovery value chain for screening, hit confirmation and selectivity. Because neither the ligand…

Read more

Impilo & Pelago Bioscience Partnership!

Impilo invests in Pelago Bioscience AB and enters a partnership to accelerate Pelago’s growth. Founded in 2013, Pelago is a fast-growing drug discovery focused contract research organisation offering services based on the patented CEllular Thermal Shift Assay (CETSA®) technology…

Read more

New CETSA® Publication – A Shift in Thinking

We are thrilled to share our latest publication in the journal “ACS Medicinal Chemistry Letters” titled – A Shift in Thinking: Cellular Thermal Shift Assay-Enabled Drug Discovery. In this study, we highlighted recently published applications of CETSA® and how the…

Read more

CETSA® Conference, september 28

Pelago Bioscience is bringing together the CETSA® community to inspire, learn and unleash drug discovery. As Pelago is expanding its portfolio of services and technologies, we remain committed to empowering our partners in accelerating drug discovery. As a part…

Read more